Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Relaxin · RLX

Recombinant protein · Agonist of RXFP1 · developed by AstraZeneca

Phase 2 Most advanced trial

AZN Developer

1 Registered trials

What is Relaxin?

Relaxin is a recombinant peptide hormone encoded by RLN2 that binds to the G protein-coupled receptor RXFP1. It is studied in cardiovascular diseases and type 2 diabetes mellitus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: RLX
Drug type: Recombinant protein
Targets: RXFP1
Mechanism: Agonist of RXFP1
Therapy area: Cardiovascular, Endocrine
Developer: AstraZeneca (AZN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03449251	Phase 2	Cardiovascular Diseases	Active not recruiting	AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cardiovascular DiseasesType 2 Diabetes Mellitus

More from AstraZeneca

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Camizestrant FDA approved Durvalumab FDA approved Olaparib FDA approved Tremelimumab FDA approved Actinium Ac 225 FPI-2068 Phase 1 Adavosertib Phase 2 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1

Sources

ClinicalTrials.gov NCT03449251

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Relaxin

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z